The oncopig cancer model as a complementary tool for phenotypic drug discovery

Natalia V. Segatto, Mariana H. Remião, Kyle M. Schachtschneider, Fabiana K. Seixas, Lawrence B Schook, Tiago Collares

Research output: Contribution to journalShort survey

Abstract

The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery. PDD, also known as phenotypic screening, consists of screening potential compounds in either in vitro cellular or in vivo animal models to identify compounds resulting in a desirable phenotypic change. Using this approach, the biological targets of the compounds are not taken into consideration. Suitable animal models are crucial for the continued validation and discovery of new drugs, as compounds displaying promising results in phenotypic in vitro cell-based and in vivo small animal model screenings often fail in clinical trials. Indeed, this is mainly a result of differential anatomy, physiology, metabolism, immunology, and genetics between humans and currently used pre-clinical small animal models. In contrast, pigs are more predictive of therapeutic treatment outcomes in humans than rodents. In addition, pigs provide an ideal platform to study cancer due to their similarities with humans at the anatomical, physiological, metabolic, and genetic levels. Here we provide a mini-review on the reemergence of PDD in drug development, highlighting the potential of porcine cancer models for improving pre-clinical drug discovery and testing. We also present precision medicine based genetically defined swine cancer models developed to date and their potential as biomedical models.

Original languageEnglish (US)
Article number894
JournalFrontiers in Pharmacology
Volume8
Issue numberDEC
DOIs
StatePublished - Dec 5 2017

Fingerprint

Drug Discovery
Neoplasms
Swine
Animal Models
Precision Medicine
Medical Genetics
Genomics
Allergy and Immunology
Pharmaceutical Preparations
Molecular Biology
Rodentia
Anatomy
Therapeutics
Research Personnel
Clinical Trials

Keywords

  • Animal model
  • Cancer
  • Oncopig cancer model
  • PDD
  • Swine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Segatto, N. V., Remião, M. H., Schachtschneider, K. M., Seixas, F. K., Schook, L. B., & Collares, T. (2017). The oncopig cancer model as a complementary tool for phenotypic drug discovery. Frontiers in Pharmacology, 8(DEC), [894]. https://doi.org/10.3389/fphar.2017.00894

The oncopig cancer model as a complementary tool for phenotypic drug discovery. / Segatto, Natalia V.; Remião, Mariana H.; Schachtschneider, Kyle M.; Seixas, Fabiana K.; Schook, Lawrence B; Collares, Tiago.

In: Frontiers in Pharmacology, Vol. 8, No. DEC, 894, 05.12.2017.

Research output: Contribution to journalShort survey

Segatto, NV, Remião, MH, Schachtschneider, KM, Seixas, FK, Schook, LB & Collares, T 2017, 'The oncopig cancer model as a complementary tool for phenotypic drug discovery', Frontiers in Pharmacology, vol. 8, no. DEC, 894. https://doi.org/10.3389/fphar.2017.00894
Segatto, Natalia V. ; Remião, Mariana H. ; Schachtschneider, Kyle M. ; Seixas, Fabiana K. ; Schook, Lawrence B ; Collares, Tiago. / The oncopig cancer model as a complementary tool for phenotypic drug discovery. In: Frontiers in Pharmacology. 2017 ; Vol. 8, No. DEC.
@article{928af3b7febc49498a9c2cef4de1871e,
title = "The oncopig cancer model as a complementary tool for phenotypic drug discovery",
abstract = "The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery. PDD, also known as phenotypic screening, consists of screening potential compounds in either in vitro cellular or in vivo animal models to identify compounds resulting in a desirable phenotypic change. Using this approach, the biological targets of the compounds are not taken into consideration. Suitable animal models are crucial for the continued validation and discovery of new drugs, as compounds displaying promising results in phenotypic in vitro cell-based and in vivo small animal model screenings often fail in clinical trials. Indeed, this is mainly a result of differential anatomy, physiology, metabolism, immunology, and genetics between humans and currently used pre-clinical small animal models. In contrast, pigs are more predictive of therapeutic treatment outcomes in humans than rodents. In addition, pigs provide an ideal platform to study cancer due to their similarities with humans at the anatomical, physiological, metabolic, and genetic levels. Here we provide a mini-review on the reemergence of PDD in drug development, highlighting the potential of porcine cancer models for improving pre-clinical drug discovery and testing. We also present precision medicine based genetically defined swine cancer models developed to date and their potential as biomedical models.",
keywords = "Animal model, Cancer, Oncopig cancer model, PDD, Swine",
author = "Segatto, {Natalia V.} and Remi{\~a}o, {Mariana H.} and Schachtschneider, {Kyle M.} and Seixas, {Fabiana K.} and Schook, {Lawrence B} and Tiago Collares",
year = "2017",
month = "12",
day = "5",
doi = "10.3389/fphar.2017.00894",
language = "English (US)",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "DEC",

}

TY - JOUR

T1 - The oncopig cancer model as a complementary tool for phenotypic drug discovery

AU - Segatto, Natalia V.

AU - Remião, Mariana H.

AU - Schachtschneider, Kyle M.

AU - Seixas, Fabiana K.

AU - Schook, Lawrence B

AU - Collares, Tiago

PY - 2017/12/5

Y1 - 2017/12/5

N2 - The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery. PDD, also known as phenotypic screening, consists of screening potential compounds in either in vitro cellular or in vivo animal models to identify compounds resulting in a desirable phenotypic change. Using this approach, the biological targets of the compounds are not taken into consideration. Suitable animal models are crucial for the continued validation and discovery of new drugs, as compounds displaying promising results in phenotypic in vitro cell-based and in vivo small animal model screenings often fail in clinical trials. Indeed, this is mainly a result of differential anatomy, physiology, metabolism, immunology, and genetics between humans and currently used pre-clinical small animal models. In contrast, pigs are more predictive of therapeutic treatment outcomes in humans than rodents. In addition, pigs provide an ideal platform to study cancer due to their similarities with humans at the anatomical, physiological, metabolic, and genetic levels. Here we provide a mini-review on the reemergence of PDD in drug development, highlighting the potential of porcine cancer models for improving pre-clinical drug discovery and testing. We also present precision medicine based genetically defined swine cancer models developed to date and their potential as biomedical models.

AB - The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery. PDD, also known as phenotypic screening, consists of screening potential compounds in either in vitro cellular or in vivo animal models to identify compounds resulting in a desirable phenotypic change. Using this approach, the biological targets of the compounds are not taken into consideration. Suitable animal models are crucial for the continued validation and discovery of new drugs, as compounds displaying promising results in phenotypic in vitro cell-based and in vivo small animal model screenings often fail in clinical trials. Indeed, this is mainly a result of differential anatomy, physiology, metabolism, immunology, and genetics between humans and currently used pre-clinical small animal models. In contrast, pigs are more predictive of therapeutic treatment outcomes in humans than rodents. In addition, pigs provide an ideal platform to study cancer due to their similarities with humans at the anatomical, physiological, metabolic, and genetic levels. Here we provide a mini-review on the reemergence of PDD in drug development, highlighting the potential of porcine cancer models for improving pre-clinical drug discovery and testing. We also present precision medicine based genetically defined swine cancer models developed to date and their potential as biomedical models.

KW - Animal model

KW - Cancer

KW - Oncopig cancer model

KW - PDD

KW - Swine

UR - http://www.scopus.com/inward/record.url?scp=85036651215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036651215&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00894

DO - 10.3389/fphar.2017.00894

M3 - Short survey

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - DEC

M1 - 894

ER -